The considerable cardiovascular benefits associated with specific GLP-1 agonists and the well-documented efficacy of GLP-1 agonists in diabetes care are two key drivers driving this industry ahead
B12 may afford advantages: it has been studied for ameliorating nausea triggered by GLP-1 RAs
Results can be noticeable within a few hours, with more pronounced benefits emerging over the next few days
Topical applications appear generally well-tolerated in small studies, but systemic safety, long-term effects, and drug interactions remain inadequately characterized
Especially during times of a changing funding landscape, we must amplify implementation research and harmonize such efforts to implement evidence-based practices to improve SUD-related health outcomes
Reported rates: Retatrutide: 9 mg: 8.8% 12 mg: 20.9% Placebo: 0.7% [9] For comparison: Tirzepatide: 0.4% in two major studies [12] This significant jump raises a clear red flag , even though most symptoms were reported as mild and rarely led to discontinuation [9]